(MENAFN- GlobeNewsWire - Nasdaq) Drug discovery, CRO outsourcing, advanced imaging, automation and cloud platforms are driving demand, alongside modified models, assay kits and stricter ethical standards.Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "In Vivo Toxicology Market Report 2026" has been added to ResearchAndMarkets.com's offering.
In Vivo Toxicology Market to Reach $7.79 Billion by 2030 as Drug Discovery and Advanced Testing Technologies Accelerate Growth
The global in vivo toxicology market is experiencing strong growth, supported by expanding pharmaceutical research and development, a rising volume of drug discovery programs, and continued advances in toxicology testing technologies. The market is projected to increase from $5.61 billion in 2025 to $6.00 billion in 2026, representing a compound annual growth rate (CAGR) of 7.0%.
Historical market growth has been driven by increasing pharmaceutical R&D activity, the growing prevalence of chronic disease studies, and wider adoption of imaging and analytical instruments. Laboratory processes have also evolved as organizations seek more reliable animal models, improved study workflows, and greater consistency in preclinical safety assessments.
The in vivo toxicology market is forecast to reach $7.79 billion by 2030, expanding at a CAGR of 6.7% from 2026. Growth during the forecast period is expected to be supported by the development of genetically modified organisms for targeted research, integration of automated and high-throughput screening systems, and increased outsourcing of toxicology testing to contract research organizations. Advances in in vivo imaging, monitoring technologies, data analysis, and study management are also expected to improve the speed and accuracy of toxicology research.
Prominent in vivo toxicology market trends include growing adoption of rodent and non-human primate models, rising demand for advanced toxicology assay kits and reagents, and expansion of immunotoxicity and genotoxicity testing services. Automated liquid handling and imaging systems are becoming increasingly important, while regulatory compliance and ethical standards continue to influence animal testing protocols. Industry participants are also investing in alternative models and strategies designed to reduce animal use while maintaining the reliability of preclinical safety data.
The increasing number of drug discoveries is a major factor driving demand for in vivo toxicology services. Advances in biotechnology are improving the understanding of disease mechanisms and supporting the development of more targeted therapies. In vivo toxicology studies help researchers assess the safety, tolerability, and potential adverse effects of investigational compounds before clinical development. These studies can identify dose-limiting toxicities and inform formulation, dosing, and risk-management strategies.
According to the Patented Medicine Prices Review Board, more than 12,000 new medicines were in clinical trials in 2023, compared with approximately 9,000 in 2022. Oncology represented 33% of the clinical pipeline, while infectious diseases and central nervous system diseases accounted for 13% and 12%, respectively. The expanding clinical pipeline is increasing the need for robust preclinical toxicology testing and supporting continued in vivo toxicology market growth.
Technology innovation is further reshaping the market. In March 2023, Charles River Laboratories International introduced Apollo, a secure cloud-based platform offering real-time access to toxicology study data. The platform supports in vivo general toxicology studies with data visualization, planning, document access, and milestone-tracking capabilities. Digital platforms of this kind can improve study transparency, streamline project planning, support budget estimation, and enable faster decision-making throughout drug development.
Strategic acquisitions are also strengthening specialized research capabilities. In October 2023, France-based preclinical contract research organization ETAP Lab SAS acquired Syncrosome SAS, which specializes in in vivo pharmacology for cardiopulmonary conditions. The transaction expanded ETAP Lab's cardiovascular and pulmonary disease model capabilities while broadening its preclinical service portfolio in cardiology and pneumology.
North America was the largest region in the in vivo toxicology market in 2025, supported by established pharmaceutical and biotechnology industries, significant R&D investment, and a mature contract research ecosystem. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The global market coverage includes Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Product: Consumables; Instruments
2) By Testing Types: Chronic Toxicity Testing; Sub-Chronic Toxicity Testing; Sub-Acute Toxicity Testing; Acute Toxicity Testing
3) By Methodology: In Vivo Animal Models; Genetically Modified Organisms; Non-Human Primate Studies; Rodent Models; Larger Mammals
4) By Application: Immunotoxicity; Systemic Toxicity; Carcinogenicity; Genotoxicity; Developmental And Reproductive Toxicity (DART); Other Applications
5) By End-User: Pharmaceutical Companies; Biosimilars Manufacturers; Contract Research Organizations (CROs); Academic And Research Institutions; Biotechnology Firms
Subsegments:
1) By Consumables: Animal Models; Reagents And Kits; Assay Kits; Toxicology Testing Media; Antibodies; Biochemicals; Buffers And Solutions; Disposable Labware; Animal Feed; Diluents
2) By Instruments: Imaging Systems; Flow Cytometers; PCR Machines; Spectrophotometers; Microscopes; Analyzers; Centrifuges; Incubators; Animal Monitoring Systems; Automated Liquid Handling Systems
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment